ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,423.80
0.51%
Dow Jones
39,387.76
0.85%
Gold vs US Dollar
2,365.545
0.80%
Brent Oil
84.195
0.29%
Bitcoin
63,150.54
0.16%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Equillium Inc (EQ)

  7. Equillium Inc (EQ) News

Equillium (EQ)

Equillium Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:EQ
DateTimeSourceHeadlineSymbolCompany
09/05/202421:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQEquillium Inc
09/05/202421:01Business WireEquillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical HighlightsNASDAQ:EQEquillium Inc
07/05/202413:00Business WireEquillium Announces Poster Presentation at the Annual Meeting of The American Association of ImmunologistsNASDAQ:EQEquillium Inc
03/04/202413:00Business WireEquillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:EQEquillium Inc
01/04/202413:00Business WireEquillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus NephritisNASDAQ:EQEquillium Inc
25/03/202420:01Business WireEquillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical HighlightsNASDAQ:EQEquillium Inc
22/03/202412:00Business WireEquillium to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Conference and the LD Micro Invitational ConferenceNASDAQ:EQEquillium Inc
08/03/202422:35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EQEquillium Inc
08/03/202421:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
23/02/202422:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
23/02/202422:09Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EQEquillium Inc
22/02/202411:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
03/01/202423:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
03/01/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
03/01/202423:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EQEquillium Inc
21/12/202313:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
21/12/202313:00Business WireEquillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac DiseaseNASDAQ:EQEquillium Inc
20/11/202316:23PR Newswire (US)EQ Bank Card launches in Québec as Carte Banque EQNASDAQ:EQEquillium Inc
20/11/202316:23PR Newswire (Canada)EQ Bank Card launches in Québec as Carte Banque EQNASDAQ:EQEquillium Inc
13/11/202314:00Business WireEquillium Presents Positive Data from Phase 1b EQUALISE Study at the 2023 Annual Meeting of the American College of RheumatologyNASDAQ:EQEquillium Inc
08/11/202321:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EQEquillium Inc
08/11/202321:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
08/11/202321:01Business WireEquillium Reports Third Quarter 2023 Financial Results and Provides Corporate and Clinical UpdatesNASDAQ:EQEquillium Inc
06/11/202313:00Business WireEquillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of NephrologyNASDAQ:EQEquillium Inc
19/10/202313:00Business WireEquillium Announces Abstracts Accepted for Presentation at the 2023 Annual Meetings of the American Society of Nephrology and the American College of RheumatologyNASDAQ:EQEquillium Inc
16/10/202313:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
16/10/202313:00Business WireEquillium Announces Preclinical Data from New Orally Deliverable Multi-Cytokine Inhibitor in Presentation at the 18th Annual Peptide Therapeutics SymposiumNASDAQ:EQEquillium Inc
05/10/202322:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EQEquillium Inc
05/10/202322:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:EQEquillium Inc
03/10/202313:00Business WireEquillium to Host Analyst & Investor DayNASDAQ:EQEquillium Inc
 Showing the most relevant articles for your search:NASDAQ:EQ

Your Recent History

LSE
POS
Plexus
LSE
TERN
Tern
LSE
AAZ
Anglo Asian Mining
LSE
SFOR
S4 Capital
LSE
CHLL
Chill Brands
LSE
PET
Petrel Resources
LSE
GDR
Genedrive
LSE
POLX
Polarean Imaging
LSE
BOO
Boohoo
LSE
MTC
Mothercare
LSE
SYME
Supply@me Capital
LSE
SCE
Surface Transforms
LSE
TYM
Tertiary Minerals
LSE
KEFI
Kefi Gold And Copper
LSE
AGL
Angle
LSE
UPS
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved